Andrew joined the TGR Board in February 2008 following retirement from his position as a Partner at PricewaterhouseCoopers (PWC). In his PWC role, Andrew led the technology practise for a period of time and specialised in fast growth and emerging technology companies working with many companies from start ups to successful global corporations. In more recent years he was the partner leading the firm’s Australian Life Sciences Practice.
Andrew has extensive experience in a wide range of technical areas including mergers and acquisitions, business and strategic planning, audit, valuation, capital raising and stock exchange listings on the Australian, NASDAQ and London Stock Exchanges. He has worked across a broad range of industries and is currently a Non Executive Director at ClearView Wealth Limited, Innate Immunotherapeutics Limited and the chairman of ServiceRocket Inc, InterAcct Solutions Pte and Elastagen Pty Ltd. He is also a member of the Audit and Compliance Committees of the Crescent Capital Private Equity Funds.
Anne Hinton, MSc, CA, GAICD
Managing Director, Chief Executive Officer
Anne joined TGR BioSciences in July 2002 having assisted in the company’s setup and initial management as a principal of her own consulting business. She is responsible for the operational, finance and company secretarial functions as well as the human resources, IT, facilities and quality management program.
She brings a strong background in financial and operational management and restructuring through her extensive experience gained across a range of industry sectors through former senior positions with KPMG and then her own consulting practice. In the latter role, Anne project managed the initial public offering of GroPep Ltd culminating with the listing of GroPep on the ASX.
She is a member of the Institute of Chartered Accountants and Chartered Secretaries of Australia.
Michael Crouch, PhD
Director, Business Development
A cell biologist by training, Michael was appointed in 2001 to develop and manage TGR’s screening technologies program. He was responsible for the concept, implementation and market launch of TGR’s SureFire® assay kit technology. Michael now leads the Business Development effort, with a focus on expanding the opportunities for TGR’s exciting immunoassay technologies. Previous positions were held at Burroughs Wellcome (USA), the Australian National University and GroPep Ltd, and he is the 2009 recipient of the prestigious Advancing BioBusiness Award.
Antony Sheehan, PhD
Chief Scientific Officer
After obtaining his PhD in 2005, Ant spent 2 years at Hospira Adelaide as a process development scientist, gaining experience in process development, protein purification, technology transfer and GMP manufacturing. Since joining TGR in 2007, Ant has played a key role in the development of TGR’s CaptSure™ platform and currently leads the R&D team for both technology and product development. Where TGR collaborates with or undertakes feasibility studies for other companies Ant coordinates the technical work programs. Ant plays a key role in aligning TGR’s technical workplans with its commercial goals and is committed to driving innovation in the research sector, particularly in the field of protein detection technologies.